Jérémy Mesple

Jérémy Mesple

Auto-generated profile, based on publicly available information

Jérémy Mesple

INSERM U932, Immunity and Cancer, Institut Curie, Paris, France

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2022 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
JGJohn A. Grout
John A. Grout
PSPhilemon Sirven
Philemon Sirven
ALAndrew M. Leader
Andrew M. Leader
SMShrisha Maskey
Shrisha Maskey
EHEglantine Hector
Eglantine Hector
HSHélène Salmon
Hélène Salmon
It is currently accepted that cancer-associated fibroblasts (CAF) participate in T-cell exclusion from tumor nests. To unbiasedly test this, we used single-cell RNA sequencing coupled with multiplex imaging on a large cohort of lung tumors. We identified four main CAF populations, two of which are associated with T-cell exclusion: (i) MYH11+αSMA+ CAF, which are present in early-stage tumors and form a single cell layer lining cancer aggregates, and (ii) FAP+αSMA+ CAF, which appear in more advanced tumors and organize in patches within the stroma or in multiple layers around tumor nests. Both populations orchestrate a particular structural tissue organization through dense and aligned fiber deposition compared with T cell–permissive CAF. Yet they produce distinct matrix molecules, including collagen IV (MYH11+αSMA+ CAF) and collagen XI/XII (FAP+αSMA+ CAF). Hereby, we uncovered unique molecular programs of CAF driving T-cell marginalization, whose targeting should increase immunotherapy efficacy in patients bearing T cell–excluded tumors. Significance: The cellular and molecular programs driving T-cell marginalization in solid tumors remain unclear. Here, we describe two CAF populations associated with T-cell exclusion in human lung tumors. We demonstrate the importance of pairing molecular and spatial analysis of the tumor microenvironment, a prerequisite to developing new strategies targeting T cell–excluding CAF. See related commentary by Sherman, p. 2501. This article is highlighted in the In This Issue feature, p. 2483

27 October 2025 in Cancer Immunology Research
Verified
Journal Article
Closed access
CBClémence Basse
Clémence Basse
ALAlexandre Lanau
Alexandre Lanau
CKCamille Kergaravat
Camille Kergaravat
JMJeremy Mesple
Jeremy Mesple
ISInes Dias da Silva
Ines Dias da Silva
NGNicolas Girard
Nicolas Girard
Thymomas are rare thymic epithelial tumors harboring a high but variable proportion of lymphocytes without obvious function. Autoimmunity is present in one third of patients at diagnosis. In this study, we performed a phenotypic, single-cell RNA sequencing and spatial analysis of both the T cells and tumoral cells. T cells at all stages of T-cell development—from immature to mature—were present in the tumor, suggesting active thymopoiesis in thymoma. However, data generated through multiple approaches suggested a maturation blockade at the double-negative to double-positive stage of T-cell development. In the mature T-cell compartment, the frequency of regulatory T cells was strongly decreased. The single-cell RNA sequencing analysis showed that the transcriptome of tumoral thymic epithelial cells (TEC) was most similar to that of nontumoral medullary TEC, but the expression of key molecules involved in positive and negative selection was defective. Multiplexed IHC consecutive staining revealed a loss of the cortex–medulla zoning in thymoma, which may be related to a decrease in the expression of T cell–targeted chemokines by tumoral TEC. Altogether, these results suggest that the thymopoiesis present in thymoma is abnormal and may be the cause of the prevalent autoimmunity observed in this disease.

4 April 2023
Verified
Other
Open access
JGJohn A. Grout
John A. Grout
PSPhilemon Sirven
Philemon Sirven
ALAndrew M. Leader
Andrew M. Leader
SMShrisha Maskey
Shrisha Maskey
EHEglantine Hector
Eglantine Hector
HSHélène Salmon
Hélène Salmon
Supplementary Table from Spatial Positioning and Matrix Programs of Cancer-Associated Fibroblasts Promote T-cell Exclusion in Human Lung Tumors

4 April 2023
Verified
Other
Open access
JGJohn A. Grout
John A. Grout
PSPhilemon Sirven
Philemon Sirven
ALAndrew M. Leader
Andrew M. Leader
SMShrisha Maskey
Shrisha Maskey
EHEglantine Hector
Eglantine Hector
HSHélène Salmon
Hélène Salmon
Supplementary Table from Spatial Positioning and Matrix Programs of Cancer-Associated Fibroblasts Promote T-cell Exclusion in Human Lung Tumors

4 April 2023
Verified
Other
Open access
JGJohn A. Grout
John A. Grout
PSPhilemon Sirven
Philemon Sirven
ALAndrew M. Leader
Andrew M. Leader
SMShrisha Maskey
Shrisha Maskey
EHEglantine Hector
Eglantine Hector
HSHélène Salmon
Hélène Salmon
Supplementary Table from Spatial Positioning and Matrix Programs of Cancer-Associated Fibroblasts Promote T-cell Exclusion in Human Lung Tumors

4 April 2023
Verified
Other
Open access
JGJohn A. Grout
John A. Grout
PSPhilemon Sirven
Philemon Sirven
ALAndrew M. Leader
Andrew M. Leader
SMShrisha Maskey
Shrisha Maskey
EHEglantine Hector
Eglantine Hector
HSHélène Salmon
Hélène Salmon
Supplementary Figure from Spatial Positioning and Matrix Programs of Cancer-Associated Fibroblasts Promote T-cell Exclusion in Human Lung Tumors